Pharmacogenomics of Antithrombotic Drugs -a Register Linkage Study With National Registries and Biobanks in Finland

Plain-language summary

This observational (non-interventional) study examined the pharmacogenomics of antithrombotic (blood-clot-preventing) drugs - how genetic differences affect drug response - using national registries in Finland. People genotyped for the CYP2C9 and VKORC1 genes who had cardiovascular conditions and had used antithrombotic drugs were included. The study had no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

VTT Technical Research Centre of Finland

Intervention

Non-interventional study

Start date

10/15/2019

Estimated completion

4/28/2020

Countries

Finland

Related genes

Locations

• Multiple Locations, Finland

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Genotyped for CYP2C9/rs1799853, CYP2C9/rs1057910 and VKORC1/rs9923231
* Diagnosed with at least one of the following:

  * Atrial Fibrillation and Flutter (I48)
  * Ischemic Heart Disease (I20-I25)
  * Cerebrovascular disease (I63,I65,I66, 167.2, I69.3-I69.8)
  * Atherosclerosis (I70)
  * Pulmonary embolism (I26)
  * Phlebitis and thrombophlebitis (I80)
  * Portal vein thrombosis (I81)
  * Other venous embolism and thrombosis (I82)
* Purchased at least one of the following drugs between January 1st 2007 - December 31st 2018:

  * Anticoagulants: Warfarin, Dabigatran, Apixaban, Rivaroxaban, Edoxaban, Heparin, Enoxaparin, Dalteparin
  * Antiplatelets: Clopidogrel, Ticagrelor, Acetylsalicylic acid

Exclusion Criteria:

* Permanent residence in Finland less than 12 months during the follow-up period
* Purchase of any of the antithrombotic drugs listed above between January 1st 2005 - December 31st 2006